Categoría: Geovanny Vicente

PALO ALTO, Calif., Aug. 5, 2020 /PRNewswire/ — Sitetracker, the global standard for managing high-volume, repeatable projects for critical infrastructure businesses, today announced it has updated its platform to provide customers AI-driven predictive reporting and dashboarding through Salesforce Einstein Analytics. With this change, Sitetracker customers are now able to gather specific, deep, and up-to-the-minute strategic actionable insights on how they deploy and maintain critical infrastructure. 

Sitetracker Project and Asset Management integrated with Einstein Analytics

Already being leveraged by leaders in financial services, manufacturing, healthcare & life sciences, retail, and the public sector, Sitetracker’s integration of Salesforce Einstein into its AppExchange solution is now available to critical infrastructure providers around the globe.   

Comments on the News

• «Our team of Sitetracker experts configure Einstein dashboards efficiently, understanding and tailoring to each customer’s unique business needs while developing industry best practices that we can share with our customers,» said Mike Di Modugno, VP of Solution Delivery at Sitetracker. «By understanding which vendors will deliver the best results, predicting turnaround times on key milestones like permitting, and accurately forecasting closeout dates, our customers can have both easier and deeper insights into their most important revenue drivers.»
• «We are excited that Sitetracker is continuing to innovate by adopting and developing AI-based solutions to enhance high-volume project and work management,» said Woodson Martin, GM of Salesforce AppExchange. «AppExchange is constantly evolving to meet the needs of our customers, and we love watching our partners evolve alongside us.»
• «We’ve invested hundreds of thousands of hours developing Sitetracker on top of the Salesforce platform, transforming the daily operations of our 25,000-plus users,» said Tim May, CTO & Co-Founder of Sitetracker. «Adding artificial intelligence via Einstein is the next step in our journey to continuously enhance our solution and provide customers access to cutting-edge technologies. Innovations like Einstein will improve both their business processes and their balance sheets. I’m excited to continue delivering these transformative analytic solutions to our fast-growing customers this year and in the years ahead.»

About Salesforce AppExchange

Salesforce AppExchange, the world’s leading enterprise cloud marketplace, empowers companies to sell, service, market and engage in entirely new ways. With more than 5,000 solutions, 7.5 million customer installs and 90,000 peer reviews, it is the most comprehensive source of cloud, mobile, social, IoT, analytics and artificial intelligence technologies for businesses. 

Salesforce, AppExchange, Einstein and others are among the trademarks of salesforce.com, inc. 

About Sitetracker, Inc.

Sitetracker, Inc. powers the successful deployment of critical infrastructure. As the global standard for managing high-volume projects, the Sitetracker Platform enables growth-focused innovators to optimize the entire asset lifecycle. From the field to the C-suite, Sitetracker enables stakeholders to optimize how they plan, deploy, maintain, and grow their capital asset portfolios. Market leaders in the telecommunications, utility, smart cities, and energy industries — such as Verizon, Ericsson, Fortis, Alphabet, British Telecom, and Vodafone — rely on Sitetracker to manage millions of sites and projects representing over $23 billion of portfolio holdings globally. For more information, visit www.sitetracker.com.

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/sitetracker-inc-announces-updates-to-sitetracker-project-and-asset-management-platform-on-salesforce-appexchange-the-worlds-leading-enterprise-cloud-marketplace-301106109.html

SOURCE Sitetracker

BOSTON, Aug. 5, 2020 /PRNewswire/ — Over the course of a few months, the COVID-19 pandemic has changed life as we know it, ushering in a wave of regulations and measures that, for many industries, will translate to long-term policy and procedural change. The way we view the world right now, from both business and personal perspectives, is entirely different from the way we viewed it prior to the onset of the pandemic.

Understandably, the travel industry finds itself especially vulnerable in this new world. The meeting and event management segment faces unique challenges as companies establish effective ways to meet despite current restrictions.

Alisa de Gaspe Beaubien, the CEO of Groupize, discusses the questions and issues facing the industry, adaptation strategies, and the increased role technology will now have to play in meeting programs. With years of travel experience and a proven track record of success in group travel management, Alisa can leverage her expertise to shed light on the new normal for meeting programs.

The reality-check

During this crisis, the companies with an SMM program and centralized tool were able to act quickly and responsibly to manage their current and future events and meetings, while also having access to valuable insights from past meetings. But, do enough companies have a travel program that includes meeting policy? According to Alisa, no.

«The reality is that for most companies – meetings and events are a blind spot,» she explains. «It was the industry’s dirty little secret that decentralized and offline management of events and meetings was the status quo. While everyone agreed there was a big risk in not managing the 43% of travel spend related to meetings, no one agreed on whose responsibility it was to fix it.  Now both the C-Suite and Travel Managers have a spotlight on this issue to close the gap in their program, to eliminate risk and liability.»

For the first time in Alisa’s career, she’s hearing stories of unabashed support from all stakeholders in an organization to solve the problem. Finally, Travel Managers are finding allies in new places, including Human Resources, Security, Finance, Marketing, and more.

«I’m not comfortable calling this point in time a ‘new normal’ because nothing about this is normal,» Alisa notes. «It has, however, established a now indisputable reality that organizations of all sizes need to change the way they manage the meetings and event category.»

Alisa makes an important point here; although the beginning of the pandemic represented a turbulent time for the industry, it also exposed shortcomings that were in desperate need of attention and action. Right now, most companies are using this pause in travel to prepare for an ever-changing travel landscape; preparations which, in many cases, have begun with new travel and meeting policies. These policies are critical, but the only way for smart companies to implement, enforce, and audit these policies is with technology.

«Travel Managers are a critical stakeholder in the return to travel. However, without technology to support their requirements for every component of a meetings program and the actual events themselves, the risk is unquantifiable,» Alisa explains. «Every company that ever thought about implementing a meeting program in the past, but decided not to, has since regretted that decision. Perhaps more importantly, companies that had not thought they needed a meeting program now recognize the value and have an urgency to take action.»

We are all in this together

While travel has slowed down, some companies have become invaluable to their customers during these trying times, solidifying their position as a ‘necessity’ for the new reality.

«The pandemic has highlighted the importance of the core tenants of our value proposition  – cost containment, risk management, and traveler safety with visibility to all stakeholders with flexible workflows. We did not need to pivot post-pandemic. We were able to stay on course with simple enhancements such as virtual and hybrid meetings. Simply put, these market conditions have elevated our solution from a nice to have to a must-have. Every company with corporate travelers has a spotlight on them to de-risk meeting management.»

«Groupize has always valued partnerships, admired competitors, and continued to learn from our customers and industry trends.  In April, we were proud to unite 12 industry leaders on an eBook:  Meetings Culture for Modern Companies – which compiled peer to peer insights and best practices to help companies structure their programs moving forward.  In mid-July, we released a Groupize Assurance, helping companies with meeting program Preparedness, Readiness, and Response. Content like this, as well as many other recent publications from industry groups such as TAMS, are invaluable in a time of rapid and continuous change. The people behind the ideas are resilient and driving change in the industry, and we really are all in this together.» 

What companies can do today

Alisa shares her belief that this moment in time will drive further innovation in many areas of the industry as we look to emerging trends and evolving industry demands. In the months ahead, the travel industry will be expected to adapt quickly to the ‘new normal,’ while acting proactively to address attendee concerns and wellness.  In-person events and meetings are mission-critical to business, whether for revenue generation, employee development, team building, customer retention, or essential reasons.

This begs the question; what is to come? And what do companies do today?

«While we added features to our platform to support both virtual and hybrid events, we recognize that people are resilient and want to travel. I hear this every day from our customers, and people want to plan new events. While the structure of meetings and events may look different for the next one to three years, they will continue.  But even if a company has just one meeting on the books in the future, they still need to manage every component every step of the way. The liability is just too large to ignore, and change is no longer an option; it’s an outright demand and mandate.»

Moving forward, industry experts agree that every event, regardless of the size and scale, will require pre-event approval, along with budget and pre-trip approvals to follow. More importantly, meeting planners, travel managers, executives, and travelers will all need to become more flexible in their process, as meeting logistics will always be in flux.

Alisa explains that core components such as dates, locations, venues, attendee lists, social distancing guidelines, attendance protocols, and virtual attendance that, in the past, never changed, will now be increasingly subject to change. Fortunately, the Groupize platform not only tracks these changes but also helps to manage them. The ability to centrally cancel all flights/hotel rooms for registered attendees in the event of a cancellation, perform contract tracing, and establish collaborative workflows will be increasingly valued and necessary. Moreover, some experts anticipate an increase in smaller and simpler meetings, a category for which Groupize is the industry leader.

«Ultimately, it’s clear that doing nothing is not an option. Technology will help companies meet their responsibilities. Just this week, we released a risk assessment calculator, aimed at helping companies calculate the risk in their program as well as in each meeting. We recognize that the focus in most organizations has moved from savings to safety, and we are developing resources to help companies understand their obligations and take action.  We want to keep the CEO’s of our customers out of the headlines for lax or incomplete policies leading to bad press. Finally, we must see ‘meeting program management’ via a new lens in order to get back to business.»

Like Zoom to WebEx

«We have spent five years listening to the needs of the industry, and have developed the easy to use, easy on the budget, easy to deploy meeting management tool that planners want to use. Our path is very similar to Zoom when market needs changed; Zoom became the virtual meeting tool of choice because of its focus on accessibility to any user. We expect a similar trajectory for Groupize as SMM standards receive a much-needed makeover in the post-pandemic world.»

Groupize is the only complete self-service meeting management platform designed for enterprise-wide use. The technology manages all of the core meeting logistics, such as venue sourcing, registration, attendee management, and travel, as well as delivers mission-critical data for both risk and spend management. The platform brings oversight and insight into the largest area of unmanaged spend in a corporation. It can manage up to 97% of meetings and events not traditionally recognized as a meeting such as training, recruiting, projects, and engagements.

Groupize simplifies event and meeting management with easy to use tools that manage all processes in the lifecycle of a corporate event, creating better outcomes for all stakeholders. «At times like these, containing costs, managing risk and minimizing liability while focusing on traveler safety is a priority for every company. We are the entry point for all employees in a company to begin to manage any and all components of a meeting,» says Alisa.

Alisa also shares that the company has some exciting enhancements in their registration module that will make Groupize the solution of choice not only for enterprise customers but SMB’s as well.

In the meantime, Groupize will continue to develop features that align with the needs of their channel partners and customers, and this includes more functionality on approvals and budgets and for use cases like projects and recruiting.  Currently, the Groupize Assurance enhancement is focused on lowering end-to-end risk related to the COVID-19 pandemic. Groupize Assurance includes modules to assess, update, and standardize managed meeting processes, policy, and logistics – making every step trackable and auditable our central platform.

«As a company, we are fortunate that we are not in a position that would require reinventing ourselves or pivoting from our core vision, we can continue to focus on our mission and ways to get better at delivering our brand promise.»

Groupize is supporting companies that are starting or restarting their meeting programs or switching vendors by offering risk-free terms.

About Groupize

Winner of Phocuswright Innovation Award, BTN Top 25 Most Influential of 2017 and Skift 2019 Corporate Travel Innovators, Groupize is committed to reinventing event management with easy to use tools that simplify all processes in the lifecycle of a corporate meeting, creating better outcomes for all stakeholders. We turn difficult into simple, make the unknown known, and put an end to tedious tasks while controlling the largest area of unmanaged spend in a corporation. For more information, please call 1.855.GROUPIZE, or visit groupize.com.

Groupize
Madison Harris

508-232-7719 x 215
mharris@groupize.com
www.groupize.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/ceo-of-groupize-talks-new-normal-in-meeting-programs-and-what-to-do-now-301106383.html

SOURCE Groupize

AUSTIN, Texas, Aug. 5, 2020 /PRNewswire/ — Elios Therapeutics, a biopharmaceutical company developing innovative personalized therapeutic cancer vaccines, today announced final data from a prospective, randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating adjuvant use of its personalized tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with Stage III or Stage IV melanoma at high risk of recurrence following complete surgical resection.

«We now have long-term data demonstrating that use of the TLPLDC vaccine for the adjuvant treatment of high-risk melanoma correlates with a 93 percent increase in patients alive at three years without their disease returning. This trial also significantly improves our understanding of the optimal method of vaccine production,» said Buddy Long, chief executive officer of Elios Therapeutics. «These new data, combined with the doubled rate of disease-free survival among patients treated with the vaccine and standard of care checkpoint inhibitors, further strengthen our confidence that the personalized TLPLDC vaccine provides a clinically meaningful benefit for people with high-risk melanoma. We look forward to advancing this vaccine with a registrational Phase III trial that will move us one step closer to bringing this important treatment to patients as soon as possible.»

The TLPLDC vaccine is a personalized treatment that is created using a patient’s own blood and tumor cells. Samples are collected at resection, frozen, and sent to the lab where they are used to create autologous tumor lysate, which is loaded into yeast cell wall particles. This combination is then introduced to the patient’s dendritic cells, leading to the creation of the final TLPLDC vaccine. The time from resection to injection of the vaccine takes approximately three weeks.

The vaccine has been studied in a large randomized Phase IIb trial, and the newly reported data is from the pre-specified 36-month disease-free survival (DFS) and overall survival (OS) assessment by vaccine formulation, stage, and checkpoint inhibition. The analysis included all randomized patients in an intent-to-treat (ITT) analysis. Two versions of the vaccine, one produced by isolating dendritic cells (DCs) from 120 mL of blood (vaccine-A) and one with DCs isolated after a single injection of filgrastim followed by 50-70 mL of blood (vaccine-B), were tested in 144 participants who were randomized to receive either version of the vaccine or placebo to prevent recurrence.

A key finding showed that treatment with vaccine-B resulted in clinical outcomes similar to placebo. Producing the vaccine with filgrastim was intended to increase white blood cell and dendritic cell counts, requiring less blood to be drawn from patients to create the vaccine. While the use of filgrastim increased DC production, it takes only 72-hours to create the vaccine which was not enough time for the DCs to mature, rendering vaccine-B ineffective. 

Importantly, vaccine-A, when compared to vaccine-B and placebo, resulted in a statistically significant improvement in 36-month DFS (51.8% vs. 23.4% vs 27.1%, respectively; p=0.027) and OS (92.9% vs. 62.8% vs 70.3%, respectively; p=0.022) in the ITT population.

Furthermore, the DFS improvement with vaccine-A was seen across both Stage III (49.7% vs. 29.4%; p=0.066) and IV (68.6% vs. 9.4%; p=0.0582) patients. Importantly, the addition of vaccine-A to current standard of care checkpoint inhibitors led to a statistically significant increase in 36-month DFS in the ITT population compared to treatment with checkpoint inhibitors alone (48.5% vs. 24.1%; p=0.039). As previously reported, treatment with the vaccine was well-tolerated with 34.7 percent of patients experiencing a treatment-related adverse event, and >90% being grades 1 or 2.

«To demonstrate a long-term survival benefit with low toxicity in a therapeutic is what we hope for in every clinical trial. Achieving this with an aggressive disease like melanoma offers great promise for patients,» said Mark B. Faries, M.D., co-director of the Melanoma Program and head of Surgical Oncology at Cedars-Sinai at The Angeles Clinic and Research Institute, and principal investigator of the study. «With data showing a two-fold increase in disease-free survival with the vaccine alone and in combination with checkpoint inhibitors, we hope to one day change the narrative for people with melanoma – turning this disease into a chronic condition that can be treated and managed over time.»           

About Melanoma
Melanoma is more likely to grow and spread than other types of skin cancer. When diagnosed and treated at an early stage, melanoma has a high cure rate, however patients with later stages of the disease carry a high risk for melanoma recurrence because some melanoma cells can remain in the body, even after surgery. In the U.S, the incidence of melanoma has increased over the past decades, with 91,270 estimated new cases and 9,320 related deaths in 2018.¹  

About the Phase IIb TLPLDC Study
This Phase IIb study is a prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of the TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine in patients with resected Stage III and IV melanoma. The primary endpoint of the trial is two-year disease-free survival (DFS), and the secondary endpoint is three-year DFS and overall survival (OS).

In the study, 144 participants were randomized to receive either the vaccine or placebo to prevent recurrence. TLPLDC or placebo vaccines were initiated within three months of completion of standard of care (SoC) therapies and were given at 0, 1, 2, 6, 12, and 18 months. The protocol was amended to allow concurrent checkpoint inhibitor therapy once approved for the adjuvant setting. Study participants were followed for recurrence per SoC. The primary efficacy analysis was performed on the intent-to-treat (ITT) and the per treatment (PT) populations as co-primary analyses given the high early recurrence rate often seen in patients with advanced melanoma. Secondary endpoints include 36-month DFS and overall survival (OS) which will be compared between the vaccinated and control groups as well as by vaccine formulation.

About TLPLDC
The TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine is a unique type of immunotherapy, both in how it is made and how it is delivered. The vaccine is personalized, meaning it is made from a patient’s tumor and blood. Every patient’s tumor has a unique antigenic profile unlike any other, and dendritic cells found in the blood are the most potent antigen-presenting cells in the body. Once TLPLDC is administered, it delivers the patient’s complete repertoire of tumor antigens to the immune system, creating a dual innate and adaptive immune response, activating fighter T cells, and triggering the immune system to recognize, and seek out and destroy any cells containing the antigens and specific mutations from their tumor. 

Historically, autologous cancer vaccines have been rather onerous to develop, sometimes taking months between the tumor biopsy and administration. Elios has simplified the process so the time from resection to injection is approximately two weeks. This makes the vaccine highly feasible and will ultimately be easy for community and academic oncologists to adopt into their practices.

The TLPLDC vaccine is currently being studied as a monotherapy and in combination with standard-of-care checkpoint inhibitor therapies in a Phase IIb clinical trial for the treatment of late-stage melanoma at leading academic cancer centers in the United States.

About Elios Therapeutics, LLC
Elios Therapeutics, LLC, a wholly owned subsidiary of Perseus Holdings, LLC., is a biopharmaceutical company developing a portfolio of innovative personalized therapeutic cancer vaccines targeting unmet medical needs across a broad range of tumor types. Elios’ lead therapeutic candidate is the TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine, a personalized therapeutic cancer vaccine that uses a proprietary particle delivery system to stimulate the body’s immune system to recognize cancer cells as foreign pathogens and fight a patient’s specific cancer. For more information, please visit www.eliostherapeutics.com.

Forward-Looking Statements
This document contains forward–looking statements relating to the Company’s strategy, objectives, business development plans and financial position. All statements other than statements of historical facts included in this document, including, without limitation, statements regarding the Company’s future financial position, strategy, anticipated investments, costs and results, status and results of clinical trials, size of patient population, plans, outcomes of product development efforts, and objectives of management for future operations, may be deemed to be forward–looking statements. You can identify forward-looking statements by words such as «anticipate,» «believe,» «could,» «estimate,» «expect,» «intend,» «may,» «plan,» «potential,» «predict,» «project,» «should,» «will,» «would,» or the negative of those terms, and similar expressions that convey uncertainty or future events or outcomes. These forward–looking statements involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results, performance, or achievements or industry results to be materially different from those contemplated, projected, forecasted, estimated or budgeted, whether expressed or implied, by these forward–looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward–looking statements as a prediction of actual results. None of these forward–looking statements constitutes a guarantee of the future occurrence of such events or of actual results. These statements are based on data, assumptions, and estimates that the Company believes are reasonable. The forward–looking statements contained in this document are made only as of the date hereof. Except as otherwise required by law, the Company expressly disclaims any obligation or undertaking to release publicly any updates of any forward-looking statements contained in this document to reflect any change in its actual results, assumptions, expectations or any change in events, factors, conditions, or circumstances on which any forward–looking statement contained in this document is based.

Contacts:

Media Relations
Vikki Christian 
Elixir Health Public Relations
+1 (424) 610-1241
vchristian@elixirhealthpr.com

¹ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68:7–30_Accessed at: https://www.ncbi.nlm.nih.gov/pubmed/29313949

View original content to download multimedia:http://www.prnewswire.com/news-releases/elios-therapeutics-personalized-cancer-vaccine-demonstrates-long-term-survival-benefit-among-high-risk-melanoma-patients-in-phase-iib-final-analysis-301106313.html

SOURCE Elios Therapeutics, LLC; Perseus Holdings USA

SCHAUFFHAUSEN, Switzerland, Aug. 5, 2020 /PRNewswire/ — TE Connectivity (NYSE: TEL), a world leader in connectivity and sensors, today unveiled a long-term sustainability and corporate responsibility strategy to better focus on the company’s vision for the future.

TE’s One Connected World strategy details a series of goals to make the world a better place as the company serves its employees, customers and shareholders.

«At TE, we have had an ongoing and transparent record of environmental, social and governance reporting through our annual corporate responsibility report and I’m proud of our progress over the past 10 years,» said CEO Terrence Curtin. «Now, we are evolving our strategy to the next level with One Connected World, which builds on our purpose of creating a safer, sustainable, productive and connected future and provides a roadmap for us to make a measurable impact over the next decade.»

TE has set nine strategic goals to meet by 2030:

• Embed sustainability in product creation at TE
• Partner with our direct and logistics suppliers to strengthen the sustainability of our supply chain; align our new construction with the Sustainable Facility Initiative
• Zero-accident workplace
• 100% of facilities in water-scarce locations meet reduction targets
• Decrease waste disposed
• 35%+ reduction in greenhouse gas emissions
• Strengthen our workplace culture, in which all differences are valued and all opinions count
• Impact 3 million people in next-generation technology education
• Implement a global human rights program

The company will measure its progress toward these goals and report out annually in its corporate responsibility report starting with the FY2020 report. Some of the work TE already does in pursuit of its vision of One Connected World is detailed in the FY2019 report. As one example, the report showcases how TE has incorporated sustainability into its operations over the past decade. The company has met greenhouse gas and energy reduction goals in 2012, 2015 and 2018.

This report also marks the first year TE’s corporate responsibility report aligns with the Sustainability Accounting Standards Board (SASB) standards. TE reports to the SASB standard specific to its industry as identified in the Sustainable Industry Classification System® (SICS®): Resource Transformation Sector — Electrical & Electronic Equipment Sustainability Accounting Standard.

To view the full FY2019 corporate responsibility report, visit TE.com/responsibility.

ABOUT TE CONNECTIVITY

TE Connectivity (NYSE: TEL) is a $13 billion global industrial technology leader creating a safer, sustainable, productive, and connected future. Our broad range of connectivity and sensor solutions, proven in the harshest environments, enable advancements in transportation, industrial applications, medical technology, energy, data communications, and the home. With nearly 80,000 employees, including more than 8,000 engineers, working alongside customers in approximately 150 countries, TE ensures that EVERY CONNECTION COUNTS. Learn more at www.te.com and on LinkedIn, Facebook, WeChat and Twitter.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/te-connectivity-sets-new-sustainability-charitable-goals-for-2030-301106378.html

SOURCE TE Connectivity Ltd.

EMERYVILLE, Calif., Aug. 5, 2020 /PRNewswire/ — Grocery Outlet Bargain Market, extreme-value grocery retailer, today announced its tenth annual Independence from Hunger^® Food Drive campaign raised over $3 million, and made an additional $1 million contribution to match the efforts of its participating store locations to support families in need – bringing the total donation for 2020 to $4 million. From June 24 through July 31, over 350 Grocery Outlet stores nationwide raised funds and collected monetary donations from customers, employees and Independent Operators to donate back to local food agencies. In the current state of school closures, children and their families in vulnerable and disadvantaged communities throughout the US are at risk of experiencing food insecurity.

According to the USDA’s latest analysis of Food Insecurity in America, over 11 million households undergo limited access to food sources and suffer from food insecurity ^[1]. In the COVID-19 era, Brookings estimates households with insufficient food supply was estimated between 22-38 percent ^[2]. This year, food agencies have experienced a staggering demand and growing need to provide food for children who have been prematurely released from annual school schedules and unable to attend summer school – resulting in record lows for food bank inventories across the country. Now more than ever, Grocery Outlet has strengthened its commitment that was born a decade ago with its Independence from Hunger campaign to find solutions that ensure all families have access to high-quality meals.

«We are extremely proud to support food agencies in our back yards across the nation, raising over $11 million since the campaign began is a big milestone we’ve reached,» said Eric Lindberg, CEO at Grocery Outlet Inc. «To celebrate Independence from Hunger’s 10^th year anniversary, it was important to augment the great work our Independent Operators do with local partners, as a company we’re excited to contribute $1M to match their efforts.»

Since its launch in 2011, the Independence from Hunger campaign efforts have collected over $11 million in total donations nationwide. Throughout the campaign, Grocery Outlet customers and employees were encouraged to contribute to the campaign through:

• Purchase of a pre-made food bags filled with an assortment of nonperishable items
• Give $5, Get $5 at the register. Donate $5 or more in a single transaction and receive a $5 coupon
• Contribution of a monetary donation through in-store and online platforms

Each of Grocery Outlet’s 350-plus stores identified local food agencies in their respective locations to partner with throughout the campaign. Grocery Outlet’s San Francisco Bay Area partner, Alameda County Community Food Bank, will receive all donations completed online at GroceryOutlet.com/Donate. In addition, Grocery Outlet has partnered with regional area partners such as, Central Pennsylvania Food Bank, Los Angeles Regional Food Bank and Oregon Food Bank, who will also receive generous donations from long-time supplier partners Campbell’s, ConAgra, Frito-Lay, Gamesa-Quaker, Harris Ranch, Kellogg’s, MW Polar Foods, PepsiCo, Tyson Foods, Sanderson Farms, Thomas Foods and United Salad (Del Monte).

No administration or collateral fees are deducted from the funds collected by Grocery Outlet.

For more information on the Independence from Hunger campaign and Grocery Outlet, visit GroceryOutlet.com.

About Grocery Outlet
Extreme-value grocery retailer Grocery Outlet, based in Emeryville, California, offers big savings on brand name products every day, at more than 350 locations in California, Idaho, Nevada, Oregon, Pennsylvania, and Washington. Grocery Outlet carries a full range of products from fresh produce, meat, deli and dairy to a wide assortment of natural and organic choices. They also offer a large selection of beer and wine, health and beauty care, as well as seasonal items. A third-generation, family-led company founded in 1946, Grocery Outlet exists to provide customers an exciting place to find WOW deals on name brands they trust. Grocery Outlet stores are run by an Independent Operator in the local community.

For more information about Grocery Outlet, please visit www.GroceryOutlet.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/grocery-outlet-raises-over-11-million-to-support-over-400-local-food-agencies-during-independence-from-hunger-campaign-since-2011-301106365.html

SOURCE Grocery Outlet

LAVAL, QC, Aug. 5, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) («Bausch Health» or the «Company»), today announced that the parties in the Canadian securities class action (Cattuci et al. v. Valeant Pharmaceuticals International Inc. et. al., Court File No.: 500-06-000783-163)) (the «Action») have agreed to resolve the Action for $94 million CAD (approximately $69 million USD), plus an additional amount for settlement administration costs, subject to court approval. The Action, filed in the Quebec Superior Court in 2015, alleged violations of Canadian securities laws regarding substantively the same matters as in the U.S. securities class action, which the Company also successfully settled. Once approved by the court, the settlement will resolve and discharge all class claims against the Company and the other defendants in the Action (the «Settlement»).

«This Settlement, together with our U.S. securities class action settlement and recent successful resolution of the legacy SEC investigation, puts an end to several of the more significant legal matters from the Valeant era and enables us to continue to focus our attention on Bausch Health today and our future,» said Joseph C. Papa, chairman and CEO of Bausch Health.

As part of the Settlement, the Company and the other defendants admit no liability and deny all allegations of wrongdoing whatsoever.

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words «anticipates,» «expects,» «intends,» «plans,» «should,» «could,» «would,» «may,» «believes,» «estimates,» «potential,» «target,» or «continue» and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in the Bausch Health’s most recent annual report on Form 10-K and detailed from time to time in Bausch Health’s other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch-health-resolves-canadian-securities-class-action-301106198.html

SOURCE Bausch Health Companies Inc.